By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Stem Cell Research have been published. According to news reporting out of Frankfurt, Germany, by NewsRx editors, research stated, "Respiratory syncytial virus (RSV) is a frequent cause of respiratory tract infectious disease (RTID) in allogeneic hematopoietic stem cell transplant (HSCT) recipients associated with a high mortality once infection has progressed from upper RTID (URTID) to lower RTID (URTID). Aerosolized ribavirin (RBV) is considered a cornerstone of treatment, but is expensive and has toxic side effects on patients and staff."
Our news journalists obtained a quote from the research from Goethe-University, "In this study, RSV infection was detected by polymerase chain reaction (PCR) from routinely collected throat swabs in HSCT patients. Infected individuals were treated according to an institutional protocol using intravenous (IV) RBV for patients with LRTID and oral ribavirin for URTID. RSV infection was diagnosed in 10 patients (median age 60 years) a median of 15 days after allogeneic HSCT for high-risk acute myeloid leukemia. Five patients with LRTID received IV RBV within 7 days after HSCT, and 5 with URTID were treated with oral RBV 12-40 days after HSCT. One patient died of septic shock associated with Pseudomonas aeruginosa-induced pneumonia 28 days after HSCT in prolonged neutropenia. All patients became RSV PCR negative on throat swabs within a median of 22 days from start of RBV. Despite severe lymphopenia, no patient treated for URTID progressed to LRTID. Neutrophil recovery was delayed in 3 patients. We show that IV and oral RBV were efficacious in preventing progression and reducing mortality of RSV infection in this small series of allogeneic HSCT recipients."
According to the news editors, the research concluded: "Randomized studies are not to be expected for this condition and therefore reporting case series could help in determining optimal RSV treatment."
For more information on this research see: Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2013;15(4):435-440. Transplant Infectious Disease can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Transplant Infectious Disease - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1399-3062)
Our news journalists report that additional information may be obtained by contacting S. Gueller, Goethe Univ Frankfurt, Inst Med Virol, D-60590 Frankfurt, Germany. Additional authors for this research include U. Duenzinger, T. Wolf, S. Ajib, S. Mousset, A. Berger, H. Martin, H. Serve and G. Bug (see also Stem Cell Research).
Keywords for this news article include: Europe, Germany, Virology, Frankfurt, Treatment, Hematology, RNA Viruses, Pneumovirinae, Mononegavirales, Bone Marrow Cells, Stem Cell Research, Pneumovirus Infections, Hematopoietic Stem Cells, Paramyxoviridae Infections, Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC